small molecule

SINUVA

MOMETASONE FUROATE

Loss of exclusivityNovember 2034latest FDA-listed patent expiry

CompanyIntersect ENT →View the full company profile on CliffBio

Drug detail

Brand name	SINUVA
Active ingredient	MOMETASONE FUROATE
Strength	1.35MG
Dosage form	IMPLANT
Route	IMPLANTATION
Modality	Small molecule
FDA approval	December 2017
Marketing status	RX

Listed patents

Patent	Expires	Type
10232152	November 2034	product
10406332	March 2034	product
8763222	February 2032	product
10357640	October 2031	use U-2272
8025635	June 2027	product
7544192	November 2026	use U-2272
9585681	April 2026	use U-2272

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.